Mika A. Sovak

5.1k total citations · 4 hit papers
22 papers, 3.9k citations indexed

About

Mika A. Sovak is a scholar working on Pulmonary and Respiratory Medicine, Reproductive Medicine and Oncology. According to data from OpenAlex, Mika A. Sovak has authored 22 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Reproductive Medicine and 9 papers in Oncology. Recurrent topics in Mika A. Sovak's work include Ovarian cancer diagnosis and treatment (12 papers), Renal cell carcinoma treatment (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Mika A. Sovak is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Renal cell carcinoma treatment (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Mika A. Sovak collaborates with scholars based in United States, United Kingdom and Australia. Mika A. Sovak's co-authors include Carol Aghajanian, Lawrence R. Nycum, Amreen Husain, Barbara A. Goff, Patricia L. Judson, Jing Yi, Stephanie V. Blank, Michael Teneriello, Gregory Zanieski and G E Sonenshein and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mika A. Sovak

22 papers receiving 3.8k citations

Hit Papers

Combined Vemurafenib and Cobimetini... 1997 2026 2006 2016 2014 2012 1997 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
    2014 1.5k citations James Larkin, Paolo A. Ascierto et al. New England Journal of Medicine profile →
  2. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    2012 970 citations Carol Aghajanian, Stephanie V. Blank et al. Journal of Clinical Oncology profile →
  3. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
    1997 613 citations Mika A. Sovak, Robert E. Bellas et al. Journal of Clinical Investigation profile →
  4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mika A. Sovak United States 14 2.1k 2.1k 1.1k 773 562 22 3.9k
Stéphanie Lheureux Canada 27 1.6k 0.7× 1.8k 0.9× 1.7k 1.5× 1.1k 1.5× 546 1.0× 153 4.3k
Hiroaki Itamochi Japan 36 1.1k 0.5× 1.8k 0.9× 1.3k 1.1× 649 0.8× 285 0.5× 139 3.6k
Anna V. Tinker Canada 27 1.7k 0.8× 1.4k 0.6× 1.9k 1.7× 829 1.1× 619 1.1× 128 4.1k
Kathleen M. Darcy United States 39 1.8k 0.9× 2.1k 1.0× 1.9k 1.6× 961 1.2× 343 0.6× 174 5.1k
Agustin A. García United States 31 1.5k 0.7× 1.1k 0.5× 836 0.7× 392 0.5× 194 0.3× 114 3.1k
Kenneth D. Swenerton Canada 26 2.2k 1.0× 1.2k 0.6× 2.3k 2.1× 667 0.9× 388 0.7× 55 4.6k
Giorgio Valabrega Italy 28 1.8k 0.9× 946 0.5× 394 0.3× 497 0.6× 477 0.8× 115 2.8k
Euan Macpherson United Kingdom 9 2.3k 1.1× 1.3k 0.6× 1.1k 1.0× 398 0.5× 290 0.5× 13 3.0k
Paula M. Fracasso United States 31 1.6k 0.8× 1.0k 0.5× 361 0.3× 380 0.5× 242 0.4× 109 3.0k
Marja Mergui‐Roelvink Netherlands 17 2.9k 1.3× 2.2k 1.1× 700 0.6× 715 0.9× 283 0.5× 31 3.9k

Countries citing papers authored by Mika A. Sovak

Since Specialization
Citations

This map shows the geographic impact of Mika A. Sovak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika A. Sovak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika A. Sovak more than expected).

Fields of papers citing papers by Mika A. Sovak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika A. Sovak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika A. Sovak. The network helps show where Mika A. Sovak may publish in the future.

Co-authorship network of co-authors of Mika A. Sovak

This figure shows the co-authorship network connecting the top 25 collaborators of Mika A. Sovak. A scholar is included among the top collaborators of Mika A. Sovak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika A. Sovak. Mika A. Sovak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 17(11). 1579–1589. 309 indexed citations breakdown →
2.
Larkin, James, Paolo A. Ascierto, Brigitte Dréno, et al.. (2014). Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma. New England Journal of Medicine. 371(20). 1867–1876. 1491 indexed citations breakdown →
3.
4.
Aisner, Joseph, Judith Manola, Shaker R. Dakhil, et al.. (2013). Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501). Journal of Thoracic Oncology. 8(8). 1075–1083. 14 indexed citations
5.
Aghajanian, Carol, Stephanie V. Blank, Barbara A. Goff, et al.. (2012). OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 30(17). 2039–2045. 970 indexed citations breakdown →
6.
7.
8.
Birrer, M. J., Heather A. Lankes, Robert A. Burger, et al.. (2012). Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC). Annals of Oncology. 23. ix81–ix82. 9 indexed citations
9.
10.
Simon, George R., Robert Ilaria, Mika A. Sovak, et al.. (2011). A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 68(5). 1233–1241. 17 indexed citations
11.
Burger, Robert A., M F Brady, Joon Haeng Rhee, et al.. (2011). Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC).. Journal of Clinical Oncology. 29(15_suppl). 5023–5023. 4 indexed citations
12.
13.
14.
Ilaria, Robert, George R. Simon, Mika A. Sovak, et al.. (2007). Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2515–2515. 7 indexed citations
15.
Sovak, Mika A., Martee L. Hensley, Jakob Dupont, et al.. (2006). Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective study. Gynecologic Oncology. 103(2). 451–457. 45 indexed citations
16.
Sovak, Mika A., Jakob Dupont, Martee L. Hensley, et al.. (2006). Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. International Journal of Gynecological Cancer. 17(1). 197–203. 43 indexed citations
17.
Sovak, Mika A., Shaokun Chuai, Sibyl Anderson, et al.. (2005). Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study. Journal of Clinical Oncology. 23(16_suppl). 5020–5020. 3 indexed citations
18.
Arsura, Marcello, Ganesh R. Panta, Lakita G. Cavin, et al.. (2003). Transient activation of NF-κB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene. 22(3). 412–425. 125 indexed citations
19.
Sovak, Mika A., et al.. (1999). The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression.. PubMed. 10(8). 537–44. 82 indexed citations
20.
Sovak, Mika A., Robert E. Bellas, Dong Wook Kim, et al.. (1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.. Journal of Clinical Investigation. 100(12). 2952–2960. 613 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphanie Lheureux Breakdown of academic impact, for papers by Hiroaki Itamochi Breakdown of academic impact, for papers by Anna V. Tinker Breakdown of academic impact, for papers by Kathleen M. Darcy Breakdown of academic impact, for papers by Agustin A. García Breakdown of academic impact, for papers by Kenneth D. Swenerton Breakdown of academic impact, for papers by Giorgio Valabrega Breakdown of academic impact, for papers by Euan Macpherson Breakdown of academic impact, for papers by Paula M. Fracasso Breakdown of academic impact, for papers by Marja Mergui‐Roelvink
Rankless by CCL
2026